ARGX N logo

argenx SEBMV:ARGX N Stock Report

Market Cap Mex$864.7b
Share Price
Mex$13.00k
Mex$15.94k
18.5% undervalued intrinsic discount
1Yn/a
7D0%
1D
Portfolio Value
​
View

argenx SE

BMV:ARGX N Stock Report

Market Cap: Mex$864.7b

argenx (ARGX N) Stock Overview

A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. More details

ARGX N fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 55.3% below our estimate of its fair value

Earnings are forecast to grow 21.63% per year

Earnings grew by 39.9% over the past year

Risk Analysis

Shares are highly illiquid


ARGX N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

argenx SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for argenx
Historical stock prices
Current Share Price€13,000.67
52 Week High€16,955.60
52 Week Low€10,590.00
Beta-0.057
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change76.44%
5 Year Changen/a
Change since IPO85.56%

Recent News & Updates

Recent updates

Shareholder Returns

ARGX NMX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how ARGX N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how ARGX N performed against the MX Market.

Price Volatility

Is ARGX N's price volatile compared to industry and market?
ARGX N volatility
ARGX N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: ARGX N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine ARGX N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,863Karen Masseyargenx.com

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.

argenx SE Fundamentals Summary

How do argenx's earnings and revenue compare to its market cap?
ARGX N fundamental statistics
Market capMex$864.74b
Earnings (TTM)Mex$25.84b
Revenue (TTM)Mex$82.29b
33.5x
P/E Ratio
10.5x
P/S Ratio

Is ARGX N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARGX N income statement (TTM)
RevenueUS$4.74b
Cost of RevenueUS$1.99b
Gross ProfitUS$2.76b
Other ExpensesUS$1.27b
EarningsUS$1.49b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 23, 2026

Earnings per share (EPS)23.94
Gross Margin58.11%
Net Profit Margin31.40%
Debt/Equity Ratio0.6%

How did ARGX N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 05:31
End of Day Share Price 2026/03/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 55 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Colleen KusyBaird
Joel BeattyBaird